Wednesday, September 07, 2022 11:31:13 PM
Where's the evidence that the post hoc protocol is FDA approved?? NWBO's SEC filing says it was not. As they said: "There can be no assurance that regulatory authorities will allow a product approval to be based upon this approach."
The crossover was part of the original trial protocol as the rescue method. There was no reason for FDA to change it as patients in cancer trials need rescue medication option. But it also confounded the naïve OS data as clearly stated by the NWBO.
If FDA had "approved" the post hoc protocol, then NWBO would have assurance that the protocol/SAP methodology would have been approvable -- but they said the opposite.
PIP has nothing to do with regulatory approval other than as a pre-requisite for an application to the MHRA. That's it. It does not mean NWBO's post hoc protocol manipulation will be acceptable.
The crossover was part of the original trial protocol as the rescue method. There was no reason for FDA to change it as patients in cancer trials need rescue medication option. But it also confounded the naïve OS data as clearly stated by the NWBO.
If FDA had "approved" the post hoc protocol, then NWBO would have assurance that the protocol/SAP methodology would have been approvable -- but they said the opposite.
PIP has nothing to do with regulatory approval other than as a pre-requisite for an application to the MHRA. That's it. It does not mean NWBO's post hoc protocol manipulation will be acceptable.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
